Allspring Global Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Allspring Global Investments’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$472K	Buy	+37,200	New	+$362K	﹤0.01%	1466
2024 Q4	–	Sell	-27	Closed	-$291	–	1986
2024 Q3	$291	Buy	+27	New	+$448	﹤0.01%	2396
2024 Q2	–	Sell	-3,457	Closed	-$110K	–	2428
2024 Q1	$110K	Buy	3,457 +3,026	+702%	+$77.2K	﹤0.01%	1824
2023 Q4	$8.73K	Sell	431 -92	-18%	-$1.21K	﹤0.01%	2031
2023 Q3	$6.66K	Buy	+523	New	+$8.75K	﹤0.01%	2656
2023 Q1	–	Sell	-12,758	Closed	-$283K	–	2822
2022 Q4	$283K	Sell	12,758 -8,190	-39%	-$127K	﹤0.01%	1747
2022 Q3	$168K	Buy	+20,948	New	+$190K	﹤0.01%	1877
2022 Q2	–	Sell	-7,806	Closed	-$118K	–	2762
2022 Q1	$118K	Sell	7,806 -905	-10%	-$14.2K	﹤0.01%	2714
2021 Q4	$191K	Buy	+8,711	New	+$214K	﹤0.01%	2643

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Allspring Global Investments's FDMT Position: Q2 2026 in Review

Allspring Global Investments opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 37,200 shares worth $472K. The stake represents ﹤0.01% of the portfolio and ranks #1466 among its holdings. This is a return to the name: Allspring Global Investments previously reported a position in FDMT as recently as Q3 2024.

Allspring Global Investments first reported a position in FDMT in Q4 2021 and has held it in 9 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Allspring Global Investments held 37,200 shares of 4D Molecular Therapeutics worth $472K as of Q2 2026.
4D Molecular Therapeutics was a new Allspring Global Investments position in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1466 holding.
Allspring Global Investments first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 9 quarters since.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.